Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
Our Discovery Services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.
Our discovery services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.
Our world-class discovery team helps you find the best therapeutic antibody and TCR drug candidates to advance your early stage pipeline.
Our venture studio 82VS activates Alloy’s platforms, discovery services groups, and company creation expertise to help brilliant scientific entrepreneurs efficiently advance new medicines pipelines.
Daedamab’s unique, sequencing-first approach blends extremely fast B cell sequencing and antibody synthesis to help Alloy partners find high quality therapeutic antibody candidates in less time.
Through an integrated service offering from target selection through to final characterized leads, Keyway empowers drug developers working against the 90% of proteins that aren’t accessible by conventional cancer immunotherapies.
We handle aspects of a CAR discovery program, from initial monoclonal antibody discovery, to engineering to CAR constructs, to transient and stable expression in various cell types, to final in vitro and in vivo characterization of functional CAR-T constructs in primary human T cells.
We accelerate partner programs by providing early insights into functional activity of therapeutic candidates generated from Alloy discovery programs across all modalities. Generally, we offer these services in line with DeepImmune for human antibody discovery and Keyway for therapeutic TCR discovery, but we can offer advice and services on a case-by-case basis for our license partners and ecosystem collaborators.
Our first platform, the ATX-Gx™, is the world’s fastest growing transgenic mouse platform for human monoclonal antibody discovery. Partners may ship mice to their labs, work with an ATX-Gx certified service provide, or engage with our flagship antibody discovery service, DeepImmune.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Learn more about licensing our platforms for use your lab or starting a campaign with DeepImmune.
We’ve built a robust unique Deep Learning and sequencing engine that characterizes immune repertoire data, rapidly identifies novel binders, and optimizes candidates by scanning the breadth of sequence variants.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
We are also active in genetic medicines, peptides, cell therapy, and drug delivery technology through new Venture Studio companies, discovery services, and internal innovation projects.
TCRS
Learn more about our work in these areas.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
San Francisco, CA
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
